People · Operator
Named in public records as an officer, director or promoter · active 2023–2026 · Other Health Care, Pharmaceuticals, Manufacturing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Paradromics, Inc. | — | Other Health Care | Series C | $96.9M | $569.6M | 2023 |
| Gilgamesh Pharma Inc. | — | Pharmaceuticals | Series C | $72.7M | $10.8M | 2026 |
| Halo Industries, Inc. | — | Manufacturing | Series C | $46.0M | $321.3M | 2024 |
Zia Huque at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Zia Huque on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dakin Sloss | 2 | 9 |
| Amy Kruse | 2 | 4 |
| Robert Berman | 1 | 4 |
| Elizabeth Stein | 1 | 4 |
| Ron Kelly | 1 | 3 |
| Thomas Krummel | 1 | 3 |
| Adam Kablanian | 1 | 3 |
| Jonathan Sporn | 1 | 2 |
| Phil Skolnick | 1 | 2 |
| Andrew Kruegel | 1 | 2 |
| James Burrows | 1 | 2 |
| Helmy Eltoukhy | 1 | 2 |
| Dan Armbrust | 1 | 1 |
| Philip Van Stockum | 1 | 1 |
| Kirk Hasserjian | 1 | 1 |
| Andrei Iancu | 1 | 1 |
| Enke Bashllari | 1 | 1 |
| Yifan Kong | 1 | 1 |
| Matthew Angle | 1 | 1 |
| Adam R Kablanian | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.